What this means
Researchers plan to measure a protein called lumican in blood and compare it with bone density and muscle strength. This study has not started reporting results, so it cannot yet show whether lumican helps.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 45 and over · About 100 postmenopausal women
- Where
- 1 site
The science
- Registered title
- Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
- Trial ID
- NCT07677072 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Osteoporosis, Postmenopausal Osteoporosis, Frailty, Fragility Fractures
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
- Ages
- 45 Years to no maximum
- Dates
- First posted Jun 30, 2026 · updated Jun 30, 2026
Registry summary
Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims to investigate the relationship between serum lumican levels, bone mineral density, muscle strength, and clinical fragility indicators in postmenopausal women. Approximately 100 participants will undergo routine osteoporosis assessment including DEXA, laboratory testing, FRAX evaluation, and handgrip strength measurement. The study will evaluate whether serum lumican levels can identify a hidden fragility phenotype beyond conventional bone mineral density measurements.
Sites (1)
- Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey, Küçükçekmece, Istanbul, Turkey (Türkiye)